News and Press Releases
Press releases
Theralase® Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer
Press ReleaseToronto, Ontario – January 18, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when...
Theralase® Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer
Press ReleaseToronto, Ontario – January 17, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a biotech company focused on the commercialization of medical lasers to eliminate pain and the develop...
Theralase® Discovers Theralase® Cold Laser Therapy Enhances Cancer Destruction for Standard Cancer Treatments
Press ReleaseToronto, Ontario – November 30, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and th...
Theralase® Increases Revenue 12% for 3Q2017 Financial Statements
Press ReleaseToronto, Ontario – November 29, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and t...
Theralase® Therapeutic Laser Technology Enhances Cancer Destruction
Press ReleaseToronto, Ontario – November 27, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and th...
Theralase® Anti-Cancer Vaccine Validated in Colorectal Cancer
Press ReleaseToronto, Ontario – November 22, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and th...
Theralase® Demonstrates 24 Months Stability of Second Clinical Batch of Lead Anti-Cancer Drug
Press ReleaseToronto, Ontario – November 21, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and t...
Theralase® Discovers New Anti-Cancer Vaccine
Press ReleaseToronto, Ontario – November 20, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and th...
Theralase® Researcher Discovers Super Potent Anti-Cancer Drugs
Press ReleaseToronto, Ontario – November 13, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and th...
Theralase® Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated
Press ReleaseToronto, Ontario – November 8, 2017 First Four Patients Treated with Company’s Anti-Cancer Treatment Achieve Pre-Defined Primary, Secondary and Exploratory Outcome Measures Theralase Technologies Inc. (“Theralase®” or the “Com...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
